Bli medlem
Bli medlem

Du är här

2020-08-03

ExpreS2ion Biotechnologies: ExpreS2ion announces exercise of 2017 warrant program

At an Extra General Meeting in ExpreS[2]ion held on April 19, 2017, it was resolved to issue warrants as part of an incentive program for employees and Board members, "the 2017 Warrant Program". The program comprised a total of 436,200 warrants, where one (1) warrant entitled to subscription of one (1) share in the Company. The employees' part of the warrant program, 327,000 warrants, stipulated a subscription price of SEK 5.80 per share. The Board's part of the warrant program, 109,200, stipulated a subscription price of SEK 6.96 per share. All warrants, corresponding to 436,200 shares have now been exercised, providing ExpreS[2]ion SEK 2,656,632.

Number of shares, share capital and dilution

The new shares have now been registered by the Swedish Companies Registration Office (Sw. Bolagsverket). The number of shares in ExpreS[2]ion has increased by 436,200, from 15,929,691 to 16,365,891 shares. The total share capital amounts to SEK 1,818,432.33. The dilution effect for the Company's existing shareholders amounted to approximately 2.67 percent.

ExpreS[2]ion's CEO Bent Frandsen comments:

"We are very pleased that fellow colleagues and the Board have managed to take part of the market value growth. We see enormous potential and look forward to keep delivering returns to our shareholders".

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se
 

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.